Artwork

Content provided by Richard L. Miller. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Richard L. Miller or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Dr. Phil Wolfson on MDMA for Terminal Illness

58:27
 
Share
 

Manage episode 123291839 series 93640
Content provided by Richard L. Miller. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Richard L. Miller or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Phil Wolfson earned his BA at Brandeis University. He went on to graduate school at New York University School of Medicine and began practicing psychotherapy and psychiatry in California between 1966 and 1972. He's licensed to practice medicine in California and Washington. Dr. Wolfson’s been an assistant clinical professor of psychiatry at the University of California San Francisco and has taught at several graduate schools. He was one of the founding members of the Heffter Research Institute, which is another psychedelic research organization, with MAPS, the Multidisciplinary Association for Psychedelic Studies.
Dr. Wolfson is Principal Investigator of a double-blind, placebo-controlled Phase 2 study, located in Marin, California, which will gather preliminary data about the safety and efficacy of MDMA-assisted psychotherapy for anxiety in 18 subjects diagnosed with a life-threatening illness. The study has received coverage in the San Francisco Chronicle, and KQED Radio on Forum with Michael Krasny, and is poised to be a game-changer in terms of bringing mainstream attention to the topic of psychedelic medicines.
This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mindbodyhealthpolitics.org/subscribe
  continue reading

306 episodes

Artwork
iconShare
 
Manage episode 123291839 series 93640
Content provided by Richard L. Miller. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Richard L. Miller or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Phil Wolfson earned his BA at Brandeis University. He went on to graduate school at New York University School of Medicine and began practicing psychotherapy and psychiatry in California between 1966 and 1972. He's licensed to practice medicine in California and Washington. Dr. Wolfson’s been an assistant clinical professor of psychiatry at the University of California San Francisco and has taught at several graduate schools. He was one of the founding members of the Heffter Research Institute, which is another psychedelic research organization, with MAPS, the Multidisciplinary Association for Psychedelic Studies.
Dr. Wolfson is Principal Investigator of a double-blind, placebo-controlled Phase 2 study, located in Marin, California, which will gather preliminary data about the safety and efficacy of MDMA-assisted psychotherapy for anxiety in 18 subjects diagnosed with a life-threatening illness. The study has received coverage in the San Francisco Chronicle, and KQED Radio on Forum with Michael Krasny, and is poised to be a game-changer in terms of bringing mainstream attention to the topic of psychedelic medicines.
This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mindbodyhealthpolitics.org/subscribe
  continue reading

306 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide